| Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer—a phase 1 study TS Uldrick, PH Gonçalves, M Abdul-Hay, AJ Claeys, B Emu, MS Ernstoff, ... JAMA oncology 5 (9), 1332-1339, 2019 | 216 | 2019 |
| Discovery of Kaposi’s sarcoma herpesvirus-encoded circular RNAs and a human antiviral circular RNA T Tagawa, S Gao, VN Koparde, M Gonzalez, JL Spouge, AP Serquiña, ... Proceedings of the National Academy of Sciences 115 (50), 12805-12810, 2018 | 160 | 2018 |
| Viral, immunologic, and clinical features of primary effusion lymphoma K Lurain, MN Polizzotto, K Aleman, M Bhutani, KM Wyvill, PH Gonçalves, ... Blood, The Journal of the American Society of Hematology 133 (16), 1753-1761, 2019 | 125 | 2019 |
| Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy TS Uldrick, SV Adams, R Fromentin, M Roche, SP Fling, PH Gonçalves, ... Science translational medicine 14 (629), eabl3836, 2022 | 73 | 2022 |
| Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases R Ramaswami, K Lurain, MN Polizzotto, I Ekwede, K Waldon, ... Blood Advances 5 (6), 1660-1670, 2021 | 61 | 2021 |
| Treatment of Kaposi sarcoma herpesvirus–associated multicentric Castleman disease K Lurain, R Yarchoan, TS Uldrick Hematology/Oncology Clinics 32 (1), 75-88, 2018 | 54 | 2018 |
| Oncologic treatment of HIV-associated Kaposi sarcoma 40 years on R Ramaswami, K Lurain, R Yarchoan Journal of Clinical Oncology 40 (3), 294-306, 2022 | 48 | 2022 |
| Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma K Lurain, R Ramaswami, R Mangusan, A Widell, I Ekwede, J George, ... Journal for immunotherapy of cancer 9 (2), 2021 | 48 | 2021 |
| Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus–associated multicentric Castleman disease R Ramaswami, K Lurain, CJ Peer, A Serquiña, V Wang, A Widell, ... Blood, The Journal of the American Society of Hematology 135 (25), 2316-2319, 2020 | 46 | 2020 |
| Safety, activity, and long-term outcomes of pomalidomide in the treatment of Kaposi sarcoma among individuals with or without HIV infection R Ramaswami, MN Polizzotto, K Lurain, KM Wyvill, A Widell, J George, ... Clinical Cancer Research 28 (5), 840-850, 2022 | 36 | 2022 |
| Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer: A real-world report from the cancer therapy using checkpoint inhibitors in people … T El Zarif, AH Nassar, E Adib, BG Fitzgerald, J Huang, TH Mouhieddine, ... Journal of Clinical Oncology 41 (21), 3712-3723, 2023 | 32 | 2023 |
| Anti-PD-1 and anti-PD-L1 monoclonal antibodies in people living with HIV and cancer K Lurain, R Ramaswami, R Yarchoan, TS Uldrick Current HIV/AIDS Reports 17, 547-556, 2020 | 32 | 2020 |
| Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate K Lurain, TS Uldrick, R Ramaswami, MN Polizzotto, PH Goncalves, ... Blood, The Journal of the American Society of Hematology 136 (19), 2229-2232, 2020 | 30 | 2020 |
| A pilot study of liposomal doxorubicin combined with bevacizumab followed by bevacizumab monotherapy in patients with advanced Kaposi sarcoma R Ramaswami, TS Uldrick, MN Polizzotto, KM Wyvill, P Goncalves, ... Clinical Cancer Research 25 (14), 4238-4247, 2019 | 26 | 2019 |
| The changing face of HIV-associated malignancies: advances, opportunities, and future directions K Lurain, R Yarchoan, R Ramaswami American Society of Clinical Oncology Educational Book 39, 36-40, 2019 | 22 | 2019 |
| Molecular genotyping and quantitation assay for rotavirus surveillance J Liu, K Lurain, SU Sobuz, S Begum, H Kumburu, J Gratz, G Kibiki, ... Journal of virological methods 213, 157-163, 2015 | 21 | 2015 |
| Assessment of cancer therapy evaluation program advocacy and inclusion rates of people living with HIV in anti–PD1/PDL1 clinical trials JE Reuss, D Stern, JC Foster, R Ramaswami, K Lurain, HX Chen, ... JAMA Network Open 3 (12), e2027110-e2027110, 2020 | 20 | 2020 |
| How immunodeficiency can lead to malignancy SY Pai, K Lurain, R Yarchoan Hematology 2021 (1), 287-295, 2021 | 19 | 2021 |
| Cancer Immunotherapy Trials Network (CITN)-12 Study Team TS Uldrick, PH Gonçalves, M Abdul-Hay, AJ Claeys, B Emu, MS Ernstoff, ... Assessment of the safety of pembrolizumab in patients with HIV and advanced …, 0 | 14 | |
| Clinical management of Kaposi sarcoma herpesvirus-associated diseases: An update on disease manifestations and treatment strategies R Patel, K Lurain, R Yarchoan, R Ramaswami Expert Review of Anti-infective Therapy 21 (9), 929-941, 2023 | 13 | 2023 |
